SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

12 Nov 2022 Evaluate
The Total revenue for the quarter ended September 2022 of  Rs. 30256.60 millions remain, more or less, the same.The Net Profit of the company registered a slight decline of -16.72% to Rs. 1646.30  millions from Rs. 1976.80 millions.The company reported a degrowth in operating Profit to 3517.60 millions from 4221.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 30256.60 28831.80 4.94 58125.80 57769.30 0.62 112871.40 158236.80 -28.67
Other Income 558.60 823.70 -32.18 945.70 1263.20 -25.13 6709.90 5898.60 13.75
PBIDT 3517.60 4221.00 -16.66 6327.30 8768.60 -27.84 21443.90 47096.90 -54.47
Interest 192.00 34.40 458.14 270.50 85.00 218.24 169.40 286.80 -40.93
PBDT 3325.60 4186.60 -20.57 6056.80 8683.60 -30.25 20527.40 46810.10 -56.15
Depreciation 1088.00 981.80 10.82 2118.50 2128.30 -0.46 4152.60 4880.00 -14.91
PBT 2237.60 3204.80 -30.18 3938.30 6555.30 -39.92 16374.80 41930.10 -60.95
TAX 591.30 1228.00 -51.85 1070.40 2427.80 -55.91 1827.70 10801.00 -83.08
Deferred Tax -30.00 7.60 -494.74 -119.90 -227.00 -47.18 -1969.30 367.60 -635.72
PAT 1646.30 1976.80 -16.72 2867.90 4127.50 -30.52 14547.10 31129.10 -53.27
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 11.63 14.64 -20.59 10.89 15.18 -28.28 19.00 29.76 -36.17

Aurobindo Pharma Share Price

1379.25 -6.40 (-0.46%)
20-Apr-2026 10:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.30
Dr. Reddys Lab 1237.90
Cipla 1238.95
Zydus Lifesciences 941.85
Lupin 2332.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×